Miist Therapeutics

Executive Summary

Miist Therapeutics is a clinical-stage biotechnology company pioneering a novel class of inhaled microparticle therapies designed to deliver systemic drug effects within seconds, bypassing the slow onset of oral medications. Headquartered in Cambridge, MA and founded in 2021, the company's platform leverages ultra-rapid pulmonary absorption to address acute conditions such as migraine, pain, anxiety, insomnia, and nausea. By targeting large, underserved markets where rapid symptom relief is critical, Miist aims to transform the standard of care for episodic and breakthrough symptoms. The company has advanced to Phase 3 clinical development, demonstrating proof-of-concept and safety in earlier trials. Its lead product candidate is focused on acute migraine, a market with high unmet need for non-oral, fast-acting alternatives to triptans and CGRP inhibitors. With a differentiated technology that could be extended to multiple indications, Miist is positioned to capture significant market share if pivotal trials succeed. The company operates in a capital-efficient manner, leveraging its platform to build a pipeline of inhaled therapies. Upcoming milestones include the completion of enrollment and top-line data readouts from Phase 3 trials, which will be critical for regulatory submission and potential partnership discussions. Miist's ability to deliver on these catalysts will determine its trajectory toward becoming a leader in rapid-onset drug delivery.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Top-Line Data for Migraine Candidate60% success
• Q1 2027Initiation of Phase 2 Trial for Pain Indication70% success
• Q4 2026Strategic Partnership or Licensing Deal30% success